Our website uses cookies to distinguish you from other users of our website to provide you with the most relevant experience by remembering your preferences and repeat visits. By clicking on ‘Accept’ you consent to our cookie policy. However, you may visit ‘Cookie Settings’ to provide a controlled consent.

Accept

News

Archive

Novadip Biosciences SA announces positive results from Phase 1/2 clinical trial in patients with severe bone non-union of the lower limb following trauma Ventyx Biosciences announces dosing of the first patient in the Phase 2 SERENITY trial of VTX958 for the treatment of moderate to severe plaque psoriasis Resolve Therapeutics completes enrollment of Phase II Long Covid clinical trial Novadip Biosciences raises additional EUR 40 Million bringing total company funding to EUR 88 Million Phase Four unveils game changing engine for LEO Constellations Ventyx Biosciences announces positive topline Phase I data for its selective allosteric TYK2 inhibitor VTX958
Back To News
Our CMO talks solutions and projects
January 31, 2018

Our CMO talks solutions and projects

Aashu Virmani, Fuzzy Logix’ CMO was interviewed recently by independent analyst and industry expert, Ron Powell. He discusses how machine learning applies to anti-money laundering using decision trees, regression and neural nets, explains indexed data management, and gives a glimpse of 2018’s exciting new projects. Listen to the podcast.

The post Our CMO talks solutions and projects appeared first on Fuzzy Logix.

Cookie Policy Privacy Policy